CCNA2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using CCNA2 mouse mAb against Hela (1), HEK293 (2), Jurkat (3), K562 (4), SK-Br-3 (5), NIH/3T3 (6) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of A431 cells using CCNA2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CCNA2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human bladder cancer tissues using CCNA2 mouse mAb with DAB staining.    

  
  

**Background of CCNA2 Antibody**

CCNA2 (Cyclin A2) is a key regulatory protein involved in cell cycle progression, primarily governing the transition from S phase to G2/M phase. It forms complexes with cyclin-dependent kinases (CDKs), such as CDK1 and CDK2. to drive DNA replication and mitotic entry. Dysregulation of CCNA2 expression is implicated in various cancers, where its overexpression often correlates with uncontrolled proliferation, genomic instability, and poor clinical outcomes.

The CCNA2 antibody is a vital tool for detecting and quantifying Cyclin A2 in research. It enables the study of cell cycle dynamics, cancer mechanisms, and therapeutic targets. In laboratory settings, this antibody is used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to analyze CCNA2 expression patterns in tissues or cultured cells. Additionally, it aids in exploring how CCNA2 interacts with CDKs or checkpoint proteins under stress or drug treatment.

Studies utilizing CCNA2 antibodies have revealed its dual role: while essential for normal cell division, its aberrant expression can trigger tumorigenesis. For example, elevated CCNA2 levels are observed in hepatocellular carcinoma, breast cancer, and gliomas, making it a potential biomarker or therapeutic target. Furthermore, research on CCNA2 inhibitors highlights its relevance in precision oncology. Overall, the CCNA2 antibody serves as a critical reagent for advancing our understanding of cell cycle biology and its implications in disease.